Symptom Assessment of Patients following Percutaneous Transesophageal Gastrostomy Tube Placement

Overview

About this study

The purpose of this study is to measure the symptom response in patients with malignant bowel obstruction who have placement of a percutaneous transesophageal gastrostomy tube.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥18 years
  • Life expectancy of 2 weeks or greater
  • Patient must have regular access to a telephone
  • Histologically proven malignancy
  • Patient has clinical evidence of malignant bowel obstruction
  • Patient has contraindication for placement of PEG tube
  • Provision of informed consent
  • Able to complete patient questionnaire alone or with assistance.  Participants must be able to speak and read English.
  • May receive chemo or radiation and hormonal therapy while on study

Exclusion Criteria: 

  • Obvious cognitive dysfunction
  • Study will exclude women who are pregnant and/or nursing
  • Presence of tracheal fistula
  • Previous or scheduled therapy for the neck.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Mark Edwin, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions